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AbstrACt
Introduction Oxygen is the most commonly administered 
drug to mechanically ventilated critically ill adults, yet 
little is known about the optimum oxygen saturation 
(SpO
2) target for these patients; the current standard 
of care is an SpO2 of 96% or above. Small pilot studies 
have demonstrated that permissive hypoxaemia (aiming 
for a lower SpO2 than normal by using a lower fractional 
inspired oxygen concentration (FIO2)) can be achieved in 
the critically ill and appears to be safe. This approach has 
not been evaluated in a National Health Service setting. It 
is possible that permissive hypoxaemia may be beneficial 
to critically ill patients thus it requires robust evaluation.
Methods and analysis Targeted OXygen therapY 
in Critical illness (TOXYC) is a feasibility randomised 
controlled trial (RCT) to evaluate whether recruiting 
patients to a study of permissive hypoxaemia is possible 
in the UK. It will also investigate biological mechanisms 
that may underlie the links between oxygenation and 
patient outcomes. Mechanically ventilated patients with 
respiratory failure will be recruited from critical care 
units at two sites and randomised (1:1 ratio) to an SpO
2 
target of either 88%–92% or ≥96% while intubated with 
an endotracheal tube. Clinical teams can adjust FIO2 and 
ventilator settings as they wish to achieve these targets. 
Clinical information will be collected before, during and 
after the intervention and blood samples taken to measure 
markers of systemic oxidative stress. The primary outcome 
of this study is feasibility, which will be assessed by 
recruitment rate, protocol adherence and withdrawal 
rates. Secondary outcomes will include a comparison of 
standard critical care outcome measures between the two 
intervention groups, and the measurement of biomarkers 
of systemic oxidative stress. The results will be used to 
calculate a sample size, likely number of sites and overall 
length of time required for a subsequent large multicentre 
RCT.
Ethics and dissemination This study was approved by 
the London - Harrow Research Ethics Committee on 2 
November 2017 (REC Reference 17/LO/1334) and received 
HRA approval on 13 November 2017. Results from this 
study will be disseminated in peer-reviewed journals, at 
medical and scientific meetings, in the NIHR Journals 
Library and patient information websites. 
trial registration number NCT03287466; Pre-results. 
IntroduCtIon
In the UK there are over 190 000 admissions 
to adult critical care units each year ( www. 
icnarc. org). Approximately 40% of these 
patients will require mechanical ventilation 
and the mortality rate in this group is approx-
imately 30%.1 2 Hypoxaemia is common 
among this cohort of patients and we lack 
evidence-based guidelines for their manage-
ment, particularly regarding what levels 
of arterial oxygenation are acceptable or 
optimal. It has been proposed that attempting 
to fully reverse hypoxaemia in critically ill 
patients may pose a greater risk of harm than 
allowing moderate hypoxaemia to persist, a 
concept called permissive hypoxaemia.3 The 
premise behind permissive hypoxaemia is 
that the interventions used to correct hypox-
aemia may themselves cause harm, in partic-
ular high concentrations of inspired oxygen, 
therefore safely minimising their use could 
be beneficial.4–7 
Oxygen has the potential to cause harm 
when used in high concentration, primarily 
via its toxic effect on the lungs.8–10 Reac-
tive oxygen species (ROS) released mainly 
from the inner mitochondrial membrane 
strengths and limitations of this study
 ► This is the first study of permissive hypoxaemia 
in critically ill patients in a National Health Service 
setting.
 ► It is a small randomised controlled trial (RCT)  to 
assess feasibility  and not the efficacy of the 
intervention.
 ► The study will compare levels of biomarkers of sys-
temic oxidative stress between the two intervention 
groups.
 ► It will provide valuable information to enable the de-
sign of future large-scale RCTs.
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during oxidative phosphorylation serve an essential role 
in cellular signalling but in excess these highly reactive 
molecules are able to destroy lipids, proteins and DNA. 
Their rate of release is determined by cellular oxygen 
tension11 and the extent of damage caused by them can 
be measured by evaluating biomarkers of tissue degrada-
tion.12 The lung parenchyma is particularly susceptible to 
oxygen toxicity in critically ill patients as a result of being 
exposed to high concentration oxygen during mechan-
ical ventilation. The threshold above which harm may be 
caused (in terms of concentration and duration of expo-
sure) in critically ill patients is unclear, but since lung 
injury is common in this patient cohort the threshold 
may well be lower than in other patients or healthy volun-
teers. During critical illness the propagation of proin-
flammatory pathways, with the activation of leucocyte and 
vascular endothelial responses further increase the ROS 
burden.13 This depletes endogenous antioxidants, which 
normally regulate ROS homoeostasis.14 As a consequence, 
oxidative stress is a key mechanism of injury in systemic 
multiorgan failure, and has been linked to increase in 
morbidity and mortality in critical illness.15 16
Oxygen is a drug with a relatively narrow therapeutic 
index. It should therefore be prescribed, administered 
and monitored in a manner comparable to other drugs 
that have toxic side effects. There appears, however, to be 
wide variation in practice regarding its use and opinions 
about oxygenation in the critically ill.17 18 This is perhaps 
the result of a paucity of evidence from robust clinical 
trials; a somewhat surprising situation given that almost 
every patient admitted to a critical care unit will receive 
supplementary oxygen. The traditional teaching that 
hypoxaemia must be avoided at all costs, may have led 
to a disregard to the potential harm caused by excessive 
oxygen, and this requires evaluation.
A small number of studies have begun to explore 
permissive hypoxaemia as a viable treatment strategy in 
the critically ill, primarily assessing feasibility and safety. 
In the first study of its kind, 105 mechanically ventilated 
patients were assessed in a before (n=51) and after (n=54) 
design.19 Following a period of standard oxygenation prac-
tice in a single centre (aiming for normal or high blood 
oxygen levels), a practice change was initiated in which 
oxygen saturation (SpO2) was maintained at 90%–92%. 
The authors of this study concluded that the conserva-
tive oxygen therapy intervention was feasible and free of 
adverse biochemical, physiological or clinical outcomes. 
A comparable strategy was used on a much larger scale 
in a two-stage model, moving from normal oxygenation 
to an SpO2 of 92%–95%.
20 These authors reported that 
mechanical ventilation time was significantly lower during 
both study (lower SpO2) phases compared with baseline. 
The adjusted intensive care unit (ICU) mortality and 
ICU-free days did not significantly differ between study 
phases but mortality decreased in reference to baseline 
for both of the low SpO2 phases. In the first multicentre 
randomised controlled trial (RCT) of permissive hypox-
aemia a total of 103 mechanically ventilated patients 
were allocated to either a conservative oxygenation 
group (SpO2 of 88%–92%) or a liberal oxygenation 
group (SpO2 of greater than or equal to 96%).
21 The 
purpose of the study was to confirm feasibility and this 
was demonstrated, along with no excess of adverse events, 
in the low SpO2 group. The most recently published trial 
of permissive hypoxaemia was a single-centre RCT that 
compared SpO2 targets of 94%–98% versus 97%–100%.
22 
The primary outcome of this study was ICU mortality, 
and the values reported were: 11.6% in the conservative 
group and 20.2% in the conventional group, giving an 
absolute risk reduction of 8.6% (1.7%–15.0%). This study 
had a number of limitations23 but still adds weight to the 
argument that permissive hypoxaemia appears to not be 
harmful and may be of benefit.
A factor of great importance to the design of future 
studies is selecting the correct ‘standard’ treatment 
group, in order that the comparison to an intervention 
of lower oxygenation is valid and meaningful. Different 
studies have approached this in different ways (either by 
aiming for an oxygenation target or by determining the 
administered concentration of oxygen). We hope this 
feasibility will evaluate our selected methodology and 
allow us to compare it to other approaches that have been 
used. We also hope the results of this study will allow us 
to understand more about other issues specific to criti-
cally ill patients such as the concomitant presence of 
anaemia, low cardiac output and acute respiratory distress 
syndrome and chronic obstructive pulmonary disease.
MEthods
The trial was designed according to the Standard 
Protocol Items: Recommendations for Interventional 
Trials statements.24
trial aim and objectives
The Targeted OXYgen therapY in Critical illness (TOXYC) 
study aims to determine whether reducing the SpO2 target 
in patients requiring mechanical ventilation is feasible (in 
terms of participant recruitment and delivery of the inter-
vention) in a National Health Service setting. In doing 
this we hope to inform future investigators who wish to 
construct larger trials in this field. The objectives are to 
construct an RCT of conventional oxygenation versus 
permissive hypoxaemia, identify any potential barriers to 
research in this field and explore biological mechanisms 
that may explain the proposed benefits from the inter-
vention. The project was favourably supported at the UK 
Critical Care Research Forum in 2016.
Primary outcome measure
The primary outcome of this study is feasibility, which will 
be assessed in the following ways: (1) The ability to recruit 
patients (recruitment rate). (2) Protocol deviations. (3) 
Rate of withdrawal from the study (in both the interven-
tion and control groups). (4) The reasons for any with-
drawal from the study.
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Feasibility of recruitment will be evaluated by moni-
toring patient screening and subsequent agreement to 
participate, along with any withdrawal of consent during 
or after the study. Implementation of the study protocol 
will be evaluated by analysing adherence to oxygenation 
targets and completion of the treatment without protocol 
deviations. Reasons for withdrawal will be assessed by the 
trial management group at the end of the study to assess 
whether there are common themes that can be addressed 
in the future.
secondary outcome measures
Measurements of oxidative stress (including 
4-hydroxynonenal, protein carbonyls, total antioxidant 
capacity and glutathione reductase) will be made in 
blood samples taken from participants, in order to under-
stand the potential biological mechanisms that link blood 
oxygen levels to clinical outcomes. In addition, routine 
clinical data and outcome measures will be collected from 
the participants to assess any adverse effects caused by the 
intervention. Finally, length of critical care stay, length of 
hospital stay, and survival at critical care unit discharge, 
30 days and 90 days will be collected. This information 
will be essential for the design of future larger trials.
trial design
TOXYC, a multicentre RCT, which will be conducted at 
two sites, is a trial of targeted oxygen therapy in adult crit-
ically ill patients receiving mechanical ventilation via an 
endotracheal tube. Sixty patients will be allocated on a 1:1 
basis to either a normal SpO2 target group or a lower than 
normal SpO2 target group. A flow diagram of the study is 
shown in figure 1. Recruitment began in February 2018 
and is planned to continue for 15 months.
selection of participants
Screening
Screening will occur as part of routine research activity on 
the two critical care units involved in the study. Research 
nurses will use medical notes to determine initial suit-
ability for the study, according to the inclusion and exclu-
sion criteria. No additional tests or examinations will be 
required to ascertain whether patients are eligible for the 
study. Screening will occur as patients are admitted to the 
critical care units to minimise the time from admission to 
enrolment.
Inclusion criteria
 ► Unplanned admission to a critical care unit.
 ► 18 years of age and above (no upper age limit).
 ► Respiratory failure forms part of the admission 
diagnosis.
 ► Enrolled within 24 hours of admission (if already intu-
bated) or within 24 hours of intubation (if intubated 
on ICU).
 ► The patient is expected to receive mechanical ventila-
tion for >72 hours.
Exclusion criteria
 ► Admission following surgery (elective or unplanned).
 ► Those patients expected to die within 24 hours of 
admission to ICU.
 ► Pregnant women.
 ► Admission postcardiac arrest.
 ► Patients with chronic lung disease known (or highly 
suspected) to have baseline SpO2 in the range of the 
intervention arm (ie, 88%–92%). 
 ► Admission post-trauma (including traumatic brain 
injury).
 ► Known sickle cell trait or disease.
 ► Ongoing significant haemorrhage or profound 
anaemia.
 ► Severe peripheral vascular disease.
 ► Severe pulmonary hypertension.
 ► Other medical conditions where mild hypoxaemia 
would be contraindicated.
 ► Patients participating in other interventional clinical 
trials.
Enrolment
Consent
Due to the severity of illness of the patients being 
recruited to this study, and the use of sedative drugs that 
Figure 1 Study flow diagram. PIS, patient information sheet.
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are required for mechanical ventilation, it is unlikely that 
potential participants will have capacity. Should a poten-
tial participant be deemed to have capacity they will be 
approached by the research team, given a patient infor-
mation sheet (PIS) and then provided with an opportu-
nity to ask questions. After an appropriate length of time, 
the research team will seek informed consent from the 
patient if they wish to participate.
If the patient lacks capacity to provide informed 
consent, a Personal Consultee (PeC) will be appointed to 
represent them. This could be the patient’s next of kin, a 
relative or close friend with whom to discuss the patient’s 
participation in the trial. The research team will seek the 
PeC’s opinion as to whether the patient would wish to 
take part in the trial, providing for them an appropriate 
version of the ethically approved PIS. If the PeC believes 
the patient would have wanted to participate in the study 
(or would not have objected to it), they will be asked to 
sign a PeC agreement form. If there is no PeC present or 
immediately available in person, opinion may be sought 
from a suitable person via the telephone and then a tele-
phone agreement form completed by a member of the 
research team.
If there is no identifiable PeC for a potential participant 
then they will be provided with a Professional Consultee 
(PrC), who is completely independent of the study. Their 
opinion will be sought as to whether it is appropriate for 
the patient to be enrolled into the study. Opinion will be 
sought in the same manner as for the PeC, involving the 
appropriate version of the ethically approved PIS.
Adequate time will be given for consideration by the 
patient or PeC/PrC to consider the information in the 
PIS and ask questions. The research team will record 
when the PIS has been given to the patient or their 
consultee. Due to the nature of this patient cohort (criti-
cally ill patients requiring substantial organ support due 
to the severity of their illness) the length of time from 
identifying a potential participant to initiating the inter-
vention is likely to be less than 24 hours. This is to avoid 
dilution of the intervention or control effect prior to its 
commencement.
If a participant who lacked capacity at the point of 
recruitment subsequently becomes able to provide 
informed consent (because they gain capacity on 
recovery from their illness), they will be informed about 
their participation in the study, provided with a PIS and 
asked whether they would be willing to provide retrospec-
tive consent. At this point the participant will be given the 
opportunity to withdraw from the study and to decide if 
the data (and blood samples) collected from them can be 
included in the final analysis.
All patient consent and consultee agreement proce-
dures will adhere to the Mental Capacity Act (2005).
Randomisation
Randomisation will be carried out online after a patient 
has been recruited to the study and an agreement form 
or consent form has been signed. It will be conducted 
in a 1:1 manner for the intervention and control groups, 
stratified by study site, using random permuted blocks 
of different sizes. The process of randomisation will be 
conducted online ( www. sealedenvelope. com).
Withdrawal
Participants will be withdrawn from the study if:
 ► The responsible clinician deems it inappropriate for 
treatment to continue due to a change in the patient’s 
condition.
 ► The chief investigator or delegated member of the 
research team deems it inappropriate for treatment to 
continue due to a change in the patient’s condition.
 ► Agreement for the patient to participate in the study 
is withdrawn by the PeC or PrC.
 ► The patient regains capacity and chooses to withdraw 
from the study.
As this is a feasibility study, patients withdrawn from the 
study will not be replaced, but the reason for withdrawal 
will be recorded.
trial treatment
Intervention
The intervention is a more conservative use of oxygen via 
the ventilator to achieve an SpO2 of 88%–92%, lower than 
normal practice in most critical care units in the UK. The 
intervention will be delivered by the participant’s clin-
ical team, which will consist of the critical care doctors 
and nurses at the two study centres. These teams will be 
provided with guidance to help keep participants within 
their target SpO2 (supplementary material 1) but this will 
not be protocolised. Due to the nature of the interven-
tion, neither the research nor the clinical teams can be 
blinded to participant group allocation.
Comparator
The control group will receive oxygen to maintain an 
SpO2 at 96% or above (standard care). As per the inter-
vention group, guidance will be provided to the clinical 
team to help maintain participants within their target 
SpO2 (online supplementary material 2).
Duration of treatment
The aim is for the intervention to be commenced as 
soon as possible after admission to the critical care unit 
(following enrolment) and end following removal of 
the participant’s endotracheal tube. Specific treatment 
end points for both groups would therefore include 
(1) Extubation. (2) Formation of a tracheostomy. (3) 
Transfer to another critical care unit. (4) Death. The 
research team will review enrolled participants daily to 
monitor adherence to SpO2 targets and provide bedside 
advice where required. No targets or limitations will be 
set for arterial PaO2 of oxygen (PaO2) or carbon dioxide 
(PaCO2). Should a patient in the study be transferred out 
of the ICU for a short period of time (eg, for an investi-
gation or intervention) the protocol will be paused until 
their return. While out of the ICU the clinical team will be 
in control of the patient’s oxygenation. Should a patient’s 
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condition deteriorate to such an extent that either the 
clinical or research team feel it not in the patient’s best 
interest to continue in the study, they will be withdrawn 
from it at that point.
Standard clinical management
Aside from the designated SpO2 targets, all other aspects 
of care will remain the same between the intervention 
and control groups. Regular arterial blood gases should 
be taken during the trial period, according to local clin-
ical guidelines; no additional arterial blood gases will be 
necessary for the purpose of the study.
data collection
Data will be collected from various sources including the 
participant’s medical records, bedside charts and hospital 
computer systems. Data will be collected from these 
primary sources by members of the research team and 
entered into an electronic clinical record form (eCRF).
Baseline data collection
 ► Patient demographics: age, gender, height and weight.
 ► Cause of respiratory failure (diagnosis).
 ► The presence of any chronic diseases.
 ► Acute Physiology and Chronic Health Evaluation 
(APACHE) II Score (and its components).
 ► Sequential Organ Failure Assessment (SOFA) Score 
(and its components).
 ► Respiratory measurements: PaO2, PaCO2, pH, SpO2, FIO2, 
ventilator settings and measures.
 ► Cardiovascular measurements: blood pressure, heart 
rate, cardiac rhythm, vasopressor/inotrope dose, fluid 
balance.
 ► Renal measurements: creatine, urine output in the past 
24 hours, the need for renal replacement therapy.
 ► Hepatic measurements: transaminases, blood clotting 
values and bilirubin.
 ► Blood lactate concentration.
Subsequent data collection during treatment
 ► Most measures will be taken daily, except for those 
specifically related to oxygenation, which will be 
collected hourly, to permit detailed analysis of compli-
ance to blood oxygenation target.
 ► Time to extubation or detachment from mechanical 
ventilation, and mechanical ventilation-free days on 
ICU.
 ► Adverse events occurring during the study period.
Follow-up
 ► Length of ICU stay.
 ► Length of hospital stay.
 ► 30-day and 90-day survival rates, and days alive out of 
hospital.
 ► Adverse events.
data management
This trial will use an eCRF and trial data will be entered into 
an approved, protected database (https://www. elsevier. 
com/ solutions/ macro). Access to the eCRF system will 
only be provided to staff with relevant authority. Partici-
pants will be given a unique subject number and subject 
identifier. Data will be entered under this identification 
number onto the central database stored on the servers. 
The database will be password protected and only acces-
sible to members of the TOXYC study team and external 
regulators if requested. At site, access will only be granted 
to staff with permission on the delegation log, and after 
training. The servers are protected by firewalls and are 
patched and maintained according to best practice. The 
physical location of the servers is protected by closed-cir-
cuit TV and security door access. The database software 
provides a number of features to help maintain data 
quality, including; maintaining an audit trail, allowing 
custom validations on all data, allowing users to raise data 
query requests and search facilities to identify validation 
failure/missing data.
The identification, screening and enrolment logs, 
linking participant identifiable data to the pseudoanony-
mised subject numbers will either be held in written form 
in a locked filing cabinet or electronically in password 
protected form on hospital computers. After completion 
of the study the identification, screening and enrolment 
logs will be stored securely by the sites for 20 years. 
sample collection, storage and processing
Blood samples will be taken from participants in order 
to evaluate oxidative stress. Samples will be taken from 
an indwelling arterial catheter that is already present in 
the patient as part of routine critical care. Blood will be 
processed at each of the two centres according to a defined 
standard operating procedure, and then stored at −80°C. 
These blood samples will be taken at baseline (shortly 
after the patient has been recruited into the study but 
prior to their treatment being commenced), and on days 
2, 3, 5 and 10 after recruitment. A number of biomarkers 
of oxidative stress will be measured, including: 4-hydrox-
yl-2-nonenal, protein carbonyls, total antioxidant capacity 
and glutathione reductase.
safety monitoring
All adverse events will be recorded in the medical records 
and reported to the appropriate body; either online to 
SITU or by email to the sponsor. Table 1 shows a basic list 
of expected adverse events that will be recorded within 
the patient’s eCRF and medical notes, but the sponsor 
will not be informed. Adverse events and serious adverse 
events will be summarised descriptively by the interven-
tional group at the end of the study.
trial monitoring and oversight
The TOXYC Trial will report to a data monitoring 
committee, and a trial steering committee will be 
appointed to provide study oversight on behalf of the 
sponsor and funder. Day-to-day management of the trial 
will be the responsibility of the trial coordinator with 
oversight from the trial management group. Permission 
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for protocol amendments will be sought via the sponsor 
and, if deemed necessary, the research ethics committee.
statistical design
No sample size calculation was performed to determine 
the number of participants required for this trial. The 
reason for this was that it is a feasibility study in which no 
formal comparative analyses are planned. The primary 
and secondary outcome measures will be presented using 
summary statistics (eg, means, SD, medians, proportions). 
Missing data, non-compliers and withdrawals will be looked 
at in detail to determine if there is any evidence of bias.
Those analysing the data will be blinded to specific 
group allocation. A CONSORT diagram will be completed, 
summarising the number of patients eligible for the study, 
the number randomised in each arm, and enumerating in 
detail those not approached (with reasons), the number 
of withdrawals (with reasons) overall and per arm. 
Recruitment rate (overall, per site and peak recruitment 
rate per month) will be determined. Monthly and cumu-
lative accrual graphs will be constructed. Baseline charac-
teristics of randomised participants will be summarised, 
including gender, age, height, weight, details of medical 
history, preintervention APACHE II and SOFA scores. 
Mean and SD, or median and IQR, will be calculated 
as appropriate. For the secondary objectives, summary 
statistics on respiratory, cardiovascular, renal and hepatic 
measurements will be calculated at the appropriate time 
points (hourly or daily). Length of stay in the critical care 
unit and in hospital will be summarised. Thirty-day and 
90-day mortality rates will be calculated, and ‘days alive 
and out-of-hospital’ determined for each patient and 
summarised using appropriate measures. Compliance 
will be assessed. For each patient, the proportion of time 
spent within the randomisation-determined SpO2 limits 
will be calculated, and summarised by treatment arm. 
Adverse events will be tabulated and grouped according 
to seriousness, severity and causality.
All variables will be checked for completeness and 
checked for the presence of outliers. Graphical depic-
tions of results will be prepared, both on a per-patient 
basis (especially for the longitudinal data such as hourly 
oxygen measurement) and grouped by intervention. 
Frequency distribution curves will be shown where appro-
priate (especially for the ‘length of stay’ measurements).
No hypothesis testing is envisaged for this feasibility 
study. The results will be used to calculate a sample size, 
likely number of sites and overall length of time required 
for a subsequent large multicentre RCT.
Patient and public involvement
In 2014, the UK Intensive Care Society published the 
results of their James Lind Alliance Priority Setting 
Partnership.25 The aim was to identify and prioritise 
unanswered questions about adult critical care that 
are important to people who have been critically 
ill, their families and the health professionals who 
care for them. One of the identified priorities for 
research was: ‘What is the best way of preventing damage 
to the lungs of patients receiving respiratory support (venti-
lation)?’. This study addresses this publicly driven 
need, by assessing a treatment strategy that has the 
potential to reduce iatrogenic lung injury to patients 
on a ventilator and therefore improve survival. At 
the Royal Free Hospital critical care unit we have a 
growing group of patients and relatives that is willing 
to assist with the development of research. This group 
was formed and is managed by our research team at 
the Royal Free Hospital. A volunteer member of the 
public from this group agreed to assist us throughout 
the study, from the application for funding to dissem-
ination of the findings. This person was a coapplicant 
on the grant application and is an invited member of 
the Trial Steering Committee. We hope that including 
a member of the public in the design and delivery of 
the study will improve the experience of participants 
in this an future clinical research projects.
ConClusIon
The results of this feasibility trial will inform 
researchers about the ability to conduct a study evalu-
ating permissive hypoxaemia in critically ill patients. 
It will provide information about recruitment rates 
in UK critical care units and help to identify any 
barriers to future research. Furthermore, results from 
Table 1 A list of expected  adverse events  that may occur during the course of the study
Respiratory Cardiovascular Haematological
 ► Reintubation
 ► Arterial desaturation
 ► Pneumothorax
 ► Pleural effusion
 ► Pneumonia
 ► Pulmonary embolism
 ► Arrhythmia
 ► Hypotension
 ► Requirement for inotropic support
 ► Anaemia
 ► Low platelet count
 ► High leucocyte count
Renal Gastrointestinal Neurological
 ► Acute kidney injury
 ► Requirement for renal support
 ► Hyperkalaemia
 ► Diarrhoea
 ► Vomiting
 ► Failure to absorb enteral feed
 ► Delirium/agitation
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oxidative stress marker analysis may highlight biolog-
ical markers of importance in the pathway between 
oxygen administration and patient outcomes.
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